Breaking News

Parenteral Facility Brought Under Irvine Brand

January 23, 2013

Avrio move aligns service portfolio to streamline processes

Irvine Pharmaceutical Services is incorporating its Avrio parenteral manufacturing facility into the Irvine brand as part of an effort to better align its service portfolio and streamline processes for clients.
 
The custom-built parenteral manufacturing facility includes three cGMP manufacturing suites, and a formulation lab and pilot suite. Features include passive restrictive access barrier system (RABS) for filling, dedicated air-handling in each suite, and video surveillance to view product development in real time.
 
“In addition to our 25-year history providing analytical CMC support, our offering of parenteral manufacturing services completes a seamless outsourcing solution for our pharmaceutical drug and device clients,” said marketing vice president Eric Hoffman. The Irvine campus, made up of three facilities, totals more than 75,000 sq. ft. of cGMP laboratories and manufacturing space.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks